Hydralazine and magnesium valproate

Phase 3Small molecule

Hydralazine and magnesium valproate is one of 94 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Cervical CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Hydralazine and magnesium valproate

NNational Institute of Cancerología

Phase 3

1 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Cancer2 trials

Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer

Completed·NNational Institute of Cancerología·Phase 2·NCT00404326·18 enrolled

Hydralazine Valproate for Cervical Cancer

Unknown status·NNational Institute of Cancerología·Phase 3·NCT00532818·143 enrolled

Ovarian Cancer1 trial

Hydralazine Valproate for Ovarian Cancer

Unknown status·NNational Institute of Cancerología·Phase 3·NCT00533299·211 enrolled

Breast Cancer1 trial

Hydralazine and Valproate Added to Chemotherapy for Breast Cancer

Terminated·NNational Institute of Cancerología·Phase 2·NCT00395655·43 enrolled

Refractory Solid Tumors1 trial

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

Completed·NNational Institute of Cancerología·Phase 2·NCT00404508·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Hydralazine and magnesium valproate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydralazine and magnesium valproate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydralazine and magnesium valproate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Cancerología company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Institute of Cancerología

Hydralazine and magnesium valproate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Cancer2 trials

Ovarian Cancer1 trial

Breast Cancer1 trial

Refractory Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News